New program helps men with advanced prostate cancer understand their treatment
NCT ID NCT04048252
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new education program for men with metastatic prostate cancer who are taking next-generation hormone therapy. The program aimed to help patients better understand their disease, stick to their medication, and improve their quality of life. 18 patients took part, and researchers checked if the program was practical and well-liked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
18 people
The number who actually took part.
- Started
-
Sep 2019
- Finished
-
Jul 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with metastatic prostate cancer and receiving next-generation hormone therapy
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with metastatic prostate cancer treated with enzalutamide or abiraterone acetate for at least 3 months * The patient must have given their free and informed consent and signed the consent form * The patient must be insured or the beneficiary of an insurance policy Exclusion Criteria: * The subject is not in a fit state to express their consent * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic prostate cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nimes
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A scanner in the operating room could show surgeons exactly where prostate cancer remains
- New PET tracer aims to light up hidden cancer targets
- Can daily adaptive radiotherapy spare healthy tissue in prostate cancer?
- Can a radioactive tracer and MRI reveal prostate Cancer's true extent?
- Five-Fraction radiation plus hormone therapy tested against High-Risk prostate cancer
- Can a 10-Hour eating window fight cancer fatigue?